Contact this trialFirst, we need to learn more about you.
Chemotherapy
Pembrolizumab + Standard Therapy for Breast Cancer
Recruiting1 awardPhase 3
Dallas, Texas
This trial is testing whether the cancer drug pembrolizumab is more effective than placebo when given with standard neoadjuvant and adjuvant therapy for high-risk early-stage ER+/HER2- breast cancer. The primary objectives are to compare pembrolizumab to placebo in terms of pathological complete response rate and event-free survival.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service